Does cost effectiveness analysis really need to abandon the incremental cost effectiveness ratio to embrace net benefit?

10 July 2020 - The central task of cost-effectiveness analysis is to identify strategies that maximise health within finite budgets.  ...

Read more →

Why it’s time to abandon the ICER

10 July 2020 - The incremental cost-effectiveness ratio (ICER) is the most commonly reported summary measure for economic evaluations of health ...

Read more →

Beyond the numbers: a critique of quantitative multi-criteria decision analysis

1 July 2020 - When setting priorities for health, there is broad agreement that a range of social values and ethical ...

Read more →

It’s time to put fairness into focus

19 June 2020 - Medicines New Zealand is today launching a digitally-enabled public awareness platform Fairness in Focus.  ...

Read more →

CMS’s proposed rule on value-based purchasing for prescription drugs: new tools for negotiating prices for the next generation of therapies

17 June 2020 - The Trump Administration has delivered significant policy advancements to lower the price of drugs and spur greater ...

Read more →

Advancing structured decision‐making in drug regulation at the FDA and EMA

11 June 2020 - FDA’s recent benefit‐risk framework was developed for improving the clarity and consistency in communicating the reasoning behind ...

Read more →

Independent review of lamotrigine sole supply decision by PHARMAC

5 June 2020 - The review was published on the PHARMAC website today and shared with people who had been ...

Read more →

Paying for value from costly medical technologies: a framework for applying value-based payment reforms

2 June 2020 - Innovative medical products offer significant and potentially transformative impacts on health, but they create concerns about rising ...

Read more →

Traditional cost effectiveness formulas and precision medicines

 1 June 2020 - Cost effectiveness analyses, which are often conducted to evaluate new medicines, use a standardised framework to ...

Read more →

Medicines with one seller and many buyers: strategies to increase the power of the payer

20 May 2020 - Andrew Rintoul and colleagues argue that collaboration and transparency increase the market power of buyers who ...

Read more →

Putting a dollar value on life? Governments already do

11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...

Read more →

International coordination needed to encourage conduct of large, decision-relevant COVID-19 clinical trials

15 May 2020 - Regulators are highlighting the need for a comprehensive international coordination mechanism to allow the conduct of ...

Read more →

Exploration of the visibility of patient input in final recommendation documentation for three health technology assessment bodies

7 May 2020 - Health technology assessment recommendations informed by patient concerns are seen to ensure democracy and legitimacy.  ...

Read more →

COVID-19: Critical Care Advisory Group

23 April 2020 - In April 2020, PHARMAC convened a group of clinical experts from across New Zealand for an ...

Read more →

Recent PHARMAC funding decisions

22 April 2020 - You may have read about PHARMAC’S decision this week to scrap a lung cancer drug funding ...

Read more →